Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VALOR: Tofersen in SOD1-ALS
NCT02623699Phase 3Completed
- Sponsor
- Biogen
- Start
- Jan 2016
- Primary completion
- Jul 2021
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 12
01
Overview
A Phase 3 trial of tofersen in amyotrophic lateral sclerosis (ALS), sponsored by Biogen. Started Jan 2016; status: completed.
02
Drugs
tofersen
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT02623699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02623699.